Ionis Pharms Inc Drug Patent Portfolio

Ionis Pharms Inc's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Ionis Pharms Inc News

JPM26: Tryngolza poised to be the first fully owned blockbuster from Ionis.

14 Jan, 2026

Sobi's Tryngolza (Olezarsen) Receives EU Approval: A Potential Game-Changer for a Rare Genetic Condition

19 Sep, 2025

Ionis Pharmaceuticals Announces Olezarsen's Effectiveness in Lowering Triglycerides and Preventing Acute Pancreatitis in ...

06 Sep, 2025

Ionis Pharmaceuticals Reaches Record Levels as Analyst Predicts Major Success for Olezarsen. - AInvest

04 Sep, 2025

See More